Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis

Author:

Endall Ryan1ORCID,McCallum Roland2,Burgess John12ORCID

Affiliation:

1. Department of Diabetes and Endocrinology, Royal Hobart Hospital, Hobart, Australia

2. School of Medicine, University of Tasmania, Hobart, Australia

Abstract

Abstract The use of high-concentration formulations of insulin is becoming more prevalent in the management of patients with diabetes mellitus. Situations of intentional overdose utilizing these agents pose particular challenges because of the altered pharmacology at large doses and the potential complications arising thereof. A patient with type 1 diabetes mellitus self-administered 4050 units of high-concentration (300 units/mL) insulin glargine, in addition to coingestants. The patient subsequently required 7 days of high-dose dextrose infusion in order to avoid hypoglycemia, with no further insulin needed during this period. The patient also developed reversible hepatic steatosis secondary to the prolonged use of high-dose dextrose. Owing to the altered pharmacology of high-concentration insulin glargine when administered at large doses in cases of intentional overdose, patients are likely to require a much longer period of supplemental dextrose support than may otherwise be expected when these agents are used at therapeutic doses. The complication of hepatic injury in the form of steatosis also needs to be considered in these patients, and should prompt the use of adaptive prescriptions of intravenous dextrose where possible.

Publisher

The Endocrine Society

Subject

Endocrinology, Diabetes and Metabolism

Reference10 articles.

1. Insulin glargine 300 U/mL: a review in diabetes mellitus;Blair;Drugs.,2016

2. The evolution of insulin glargine and its continuing contribution to diabetes care;Hilgenfeld;Drugs.,2014

3. New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL-1;Becker;Diabetes Care.,2015

4. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo;Heinemann;Diabetes Care.,2000

5. Octreotide for the treatment of hypoglycemia after insulin glargine overdose;Groth;J Emerg Med.,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3